2023 World Conference on Lung Cancer (Posters)-EP11.03. Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials

EP11.03. Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the outcomes of immunotherapy compared to chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC) through a meta-analysis of randomized clinical trials. The researchers identified relevant studies from various databases and included phase III trials reporting overall survival (OS) in patients with advanced NSCLC. The data were stratified based on histology, PD-L1 expression, and gene mutations. The results showed that patients who received immune checkpoint inhibitors (ICIs) had improved OS compared to those who received chemotherapy alone, regardless of histology or PD-L1 status. However, the addition of ICIs to chemotherapy did not improve OS in patients with STK11 or KEAP1 mutations. Interestingly, the use of doublet ICI regimens was able to overcome resistance in patients with these mutations and improved OS. Overall, the findings suggest that the combination of ICIs and chemotherapy can improve survival outcomes in advanced NSCLC, regardless of PD-L1 expression or histology. However, the presence of specific gene mutations may impact the efficacy of single-agent ICIs, highlighting the importance of personalized treatment approaches.

Asset Subtitle

Ben Ponvilawan

Meta Tag

Speaker Ben Ponvilawan

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

immunotherapy

chemotherapy

NSCLC

meta-analysis

overall survival

PD-L1 expression

gene mutations

immune checkpoint inhibitors

histology

personalized treatment approaches